Patent Eligibility For Genome Sequencing Techniques And Plant Dna Modification Systems

20 Mar 2026 --
0 Comments

1. Legal Framework for Patent Eligibility in Biotechnology

In the U.S., patent eligibility is governed by 35 U.S.C. § 101, which allows patents on:

Processes
Machines
Manufactures
Compositions of matter

However, Supreme Court decisions have placed limits, especially on:

Natural phenomena
Laws of nature
Products of nature

For genome sequencing and plant DNA modification:

Natural DNA sequences may not be patentable unless altered in a non-naturally occurring way.
Methods that apply sequencing or modification in a specific technical process can be patentable.
Software and algorithmic methods for genome analysis may face scrutiny as abstract ideas unless tied to a specific technical improvement.

2. Key Challenges

Genome sequencing: Claims purely covering the sequence of DNA or its discovery are often rejected as natural phenomena.
Plant DNA modification: Claims must involve human-made modifications; naturally occurring genes are not patentable.
Methods must demonstrate a practical, technical application, not just a scientific observation.

3. Important Case Laws

Here are six key cases relevant to genome sequencing and plant DNA modification:

A. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

Facts:
Myriad Genetics patented isolated DNA sequences (BRCA1 and BRCA2) associated with breast cancer.

Ruling:

Naturally occurring DNA sequences cannot be patented, even if isolated.
cDNA (complementary DNA, which is synthetically created) can be patent-eligible because it is not naturally occurring.

Implications:

Genome sequencing patents cannot claim raw sequences of natural DNA.
Synthetic modifications or methods that manipulate DNA for analysis or therapeutic use may be eligible.

B. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012)

Facts:
Patent claimed a method of optimizing drug dosage based on metabolite levels.

Ruling:

The Court ruled it was not patent-eligible because it claimed a natural law and routine steps.

Implications:

Genome sequencing techniques that merely observe or measure natural sequences may be rejected unless they involve specific technological processes.
Methods that improve sequencing speed or accuracy could be eligible.

C. Diamond v. Chakrabarty, 447 U.S. 303 (1980)

Facts:
Chakrabarty genetically engineered a bacterium that could break down crude oil.

Ruling:

Genetically modified organisms can be patentable because they are human-made inventions, not naturally occurring.

Implications:

Plant DNA modification systems that create non-naturally occurring plants or traits are patent-eligible.
Mere discovery of a gene in a plant does not qualify.

D. AMP v. USPTO / Harvard Oncomouse Cases (1980s–1990s)

Facts:

Harvard researchers created genetically modified mice (Oncomouse) for cancer research.

Ruling:

The Oncomouse was patentable because it contained human-made DNA modifications, not found in nature.

Implications:

In plant biotechnology, modified crops with engineered resistance or enhanced traits are similarly patent-eligible.
Functional modifications (e.g., inserting a gene for drought resistance) are key.

E. Sequenom v. Ariosa Diagnostics, 788 F.3d 1371 (Fed. Cir. 2015)

Facts:
Sequenom patented a method for detecting fetal DNA in maternal blood.

Ruling:

The court invalidated the patent, ruling that detecting natural phenomena using routine methods is not patentable.

Implications:

Sequencing methods that merely detect existing DNA or variants without inventive techniques may be rejected.
Technical innovation in sequencing methods or sample preparation is essential.

F. Ariosa v. Sequenom and Clarification on Method Claims (Post-2015)

Facts:
The key focus was on patent-eligibility of methods using natural phenomena.

Ruling:

Even method claims must demonstrate something more than routine laboratory techniques applied to a natural phenomenon.

Implications:

DNA modification systems must claim specific processes that modify DNA in novel ways or improve sequencing technology.

4. Summary of Patent Eligibility Principles

Area	Eligible	Not Eligible	Key Considerations
Genome sequencing	Methods improving sequencing speed, accuracy, or sample preparation	Pure discovery of natural sequences	Must involve technical innovation, not just observation
Plant DNA modification	Plants or seeds with human-made traits	Naturally occurring plant genes	Must be non-naturally occurring, show functional improvement
Methods/software	Algorithms tied to specific lab hardware or modification processes	Abstract computational steps	Tie to specific technology or industrial application
DNA measurement	Novel detection tools or processes	Routine detection of natural phenomena	Avoid claiming laws of nature

5. Takeaways

Natural DNA sequences are not patentable, but engineered DNA is.
Genome sequencing methods must go beyond observation—they must involve technical processes or improvements.
Plant DNA modification is patentable when the plant or trait is human-made and non-natural.
Methods that combine sequencing, modification, and practical application (like crop improvement) have a stronger chance of being patent-eligible.